X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21747) 21747
Book Chapter (58) 58
Dissertation (56) 56
Magazine Article (56) 56
Conference Proceeding (33) 33
Book / eBook (14) 14
Government Document (11) 11
Web Resource (10) 10
Newsletter (6) 6
Publication (5) 5
Streaming Video (5) 5
Newspaper Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19623) 19623
science & technology (14385) 14385
life sciences & biomedicine (13981) 13981
male (7761) 7761
hematology (7291) 7291
female (7134) 7134
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6658) 6658
oncology (6525) 6525
adult (6400) 6400
leukemia, myelogenous, chronic, bcr-abl positive - genetics (5951) 5951
middle aged (5881) 5881
leukemia, myelogenous, chronic, bcr-abl positive - pathology (4920) 4920
chronic myeloid leukemia (4120) 4120
imatinib mesylate (4109) 4109
fusion proteins, bcr-abl - genetics (3932) 3932
aged (3598) 3598
benzamides (3332) 3332
leukemia, myelogenous, chronic, bcr-abl positive - therapy (3282) 3282
leukemia (3115) 3115
antineoplastic agents - therapeutic use (3044) 3044
pyrimidines - therapeutic use (2798) 2798
animals (2527) 2527
adolescent (2474) 2474
piperazines - therapeutic use (2400) 2400
treatment outcome (2070) 2070
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (2041) 2041
abridged index medicus (1997) 1997
hemic and lymphatic diseases (1961) 1961
philadelphia chromosome (1878) 1878
protein kinase inhibitors - therapeutic use (1832) 1832
bcr-abl (1712) 1712
fusion proteins, bcr-abl - metabolism (1706) 1706
mice (1660) 1660
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (1657) 1657
imatinib (1608) 1608
prognosis (1443) 1443
cml (1442) 1442
child (1430) 1430
cancer (1376) 1376
antineoplastic agents - pharmacology (1338) 1338
pyrimidines - pharmacology (1332) 1332
k562 cells (1307) 1307
mutation (1307) 1307
bone marrow transplantation (1301) 1301
protein-tyrosine kinases - antagonists & inhibitors (1244) 1244
leukemia, myelogenous, chronic, bcr-abl positive - complications (1205) 1205
research (1171) 1171
piperazines - pharmacology (1161) 1161
leukemia, myelogenous, chronic, bcr-abl positive (1151) 1151
tumor cells, cultured (1149) 1149
aged, 80 and over (1113) 1113
leukemia, myelogenous, chronic, bcr-abl positive - mortality (1093) 1093
cell biology (1079) 1079
biochemistry & molecular biology (1071) 1071
care and treatment (1071) 1071
leukemia, myelogenous, chronic, bcr-abl positive - blood (1069) 1069
drug resistance, neoplasm (1067) 1067
young adult (1054) 1054
apoptosis (1049) 1049
transplantation (1039) 1039
cell line, tumor (1030) 1030
leukemia, myelogenous, chronic, bcr-abl positive - immunology (1029) 1029
transplantation, homologous (1029) 1029
polymerase chain reaction (1016) 1016
apoptosis - drug effects (986) 986
fusion proteins, bcr-abl - antagonists & inhibitors (984) 984
remission induction (974) 974
dasatinib (961) 961
genetic aspects (943) 943
chronic myelogenous leukemia (939) 939
antineoplastic agents - adverse effects (925) 925
time factors (908) 908
protein kinase inhibitors - pharmacology (892) 892
antineoplastic combined chemotherapy protocols - therapeutic use (885) 885
tyrosine (876) 876
pyrimidines - adverse effects (871) 871
immunology (860) 860
analysis (854) 854
hematology, oncology and palliative medicine (852) 852
translocation, genetic (848) 848
base sequence (837) 837
pyrimidines - administration & dosage (828) 828
molecular sequence data (817) 817
karyotyping (812) 812
bone marrow - pathology (810) 810
precursor cell lymphoblastic leukemia-lymphoma - genetics (808) 808
follow-up studies (804) 804
genetics & heredity (797) 797
stem cells (794) 794
retrospective studies (793) 793
risk factors (780) 780
reverse transcriptase polymerase chain reaction (773) 773
in situ hybridization, fluorescence (769) 769
interferon-alpha - therapeutic use (768) 768
hematopoietic stem cell transplantation (764) 764
recurrence (759) 759
child, preschool (743) 743
pharmacology & pharmacy (725) 725
gene expression (717) 717
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (712) 712
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19664) 19664
Chinese (1180) 1180
Japanese (634) 634
French (236) 236
Russian (222) 222
German (212) 212
Spanish (208) 208
Polish (120) 120
Italian (78) 78
Portuguese (75) 75
Czech (50) 50
Hungarian (50) 50
Danish (22) 22
Dutch (15) 15
Korean (15) 15
Romanian (12) 12
Ukrainian (12) 12
Norwegian (10) 10
Serbian (8) 8
Hebrew (7) 7
Slovak (7) 7
Turkish (7) 7
Croatian (6) 6
Finnish (6) 6
Swedish (6) 6
Bulgarian (3) 3
Persian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2013, ISBN 1615190678, xiii, 303 p., [8] p. of plates
Book
Journal of clinical oncology, ISSN 1527-7755, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development | Index Medicus
Journal Article
Cancer Letters, ISSN 0304-3835, 2015, Volume 360, Issue 2, pp. 245 - 256
Journal Article
Cancer cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 428 - 442
Journal Article